M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Consortium led by Fall Line Endurance Fund to acquire GreenLight Biosciences Holdings, PBC
Announced May 30, 2023 · Closed Jul 24, 2023
Deal value$46MEV $13M
Premium50.0%To unaffected price
EV / Adj. EBITDA—1.3x EV / Revenue
ConsiderationAll cash$0.30 per share
Transaction
- Acquirer
- Consortium led by Fall Line Endurance Fund
- Target
- GreenLight Biosciences Holdings, PBC
- Buyer type
- Private equity
- Offer price per share
- $0.30
- Enterprise value
- $13M
- Status
- Closed Jul 24, 2023
Deal protections
- Break fee (target pays)
- —
- Reverse fee (buyer pays)
- —
- Go-shop
- 30-day go-shop
- Financing
- —
Advisors
- To the acquirer
- Not disclosed
- To the target
- Roth Capital
Sector context · Healthcare
- Comparable deals
- 81 in the prior 24 months
- Premium
- 50.0% vs. 50.0% sector median
- EV / Adj. EBITDA
- Sector median 19.3x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedMay 30, 2023
- Tender offerJun 21, 2023
- ClosedJul 24, 2023